Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

13 results about "Pharmacologic Agent" patented technology

USPRwire, Sun Nov 08 2015] Drug eluting stent, also known as medicated coronary stent, is a tiny, expandable metal mesh tube that is covered with a pharmacologic agent.

Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylate

The invention provides methods of chemical synthesis of the pharmacological agent 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate, also called CV-8972. The methods entail formation of a free base form of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanol, also called CV-8814, as intermediate without producing a salt form of CV-8814.
Owner:IMBRIA PHARMACEUTICALS INC

AI-Assisted Raman Spectroscopy System for Biomarker Analysis of Aqueous Humor

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.
Owner:REYNARD MICHAEL

System and method for personalized dosing of pharmacologic agents

A system and method for personalized dosing of a pharmacologic agent include: executing, using a processing device, a plurality of dosing regimen program modules to determine a respective plurality of dose sets in response to receiving, from an input device, a target response value for a patient; and executing, using the processing device, a dosing selection algorithm module, following executing the plurality of dosing regimen program modules and in response to receiving from the input device a response profile and a monitoring frequency of the patient, to determine a recommended dose set computed as a combination of the plurality of dose sets weighted by degrees of matching computed using fuzzy sets and the response profile.
Owner:UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC

Neuromodulation for treatment of brain and eye strokes and / or acute dysregulated reduced cerebral or ocular blood flow

ActiveUS12179021B2Ultrasound therapyHydroxy compound active ingredientsNasal vestibuleCerebral paralysis
Disclosed are devices, systems and methods for non-invasive neuromodulation system for prompt treatment of cerebral and / or ocular strokes caused by acute dysregulated reduced cerebral blood flow (CBF) and / or ocular blood flow (OBF) by up regulation of trigeminovascular system (TVS), and trigeminal autonomic brain reflexes (TABRs) through stimulation of ophthalmic nerve. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated centrally by intravenous administration of pharmacological dose of ascorbic acid. The site of stimulation of ophthalmic nerve includes but not limited to nasal vestibule, nasal bridge, and forehead and upper eyelid. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for cerebral and ocular strokes. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in cerebral arteries, leptomeningeal collaterals and ophthalmic artery by the release of Vasoactive intestinal peptide (VIP), substance P and CGRP thereof increasing cerebral and / or OBF to the brain and the eye in subject's with acute dysregulated, reduced cerebral and / or OBF. The invention, in some embodiments thereof, is also relates to upregulation of TVS in a manner that is effective to induce acute development of leptomeningeal collateral circulation sufficient to ameliorate the ischemic effect of occluded cerebral artery, enhances successful recanalization, decreases the infarction volume and improves brain functional recovery without hemorrhagic transformation. In some embodiments TVS and ANS are also modulated in a manner that induce an acute increase in choroidal blood flow sufficient to ameliorate the ischemic effect of occluded artery until spontaneous recanalization of the occluded artery is accomplished. The invention is related to targeting the affected side via ipsilateral ONS without inducing intracerebral vascular steal phenomenon. The invention, in some embodiments thereof, is also relates to the methods for improving delivery of oxygen, glucose, anticoagulants, hormones, humoral mediators, growth factors and pharmacological agents to the targeted ischemic tissues of the brain, retina and optic nerve. The methods of the invention, when combined with r-tPA treatment and / or endovascular recanalization increases window time of treatment of stroke, enhance the efficacy of treatment and reduce its side effects. The methods of the invention, in some embodiments thereof, include priming of the brain, retina and / or optic nerve thereof to enhance the efficacy of cell transplantation therapy after exposure to stroke. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment. The cerebral / and or OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.
Owner:MUSALLAM ISMAIL MOHAMMED YOUSIF

Compositions, systems and methods for treating suprapubic fat

Compositions, systems and methods are provided for the treatment of suprapubic fat, wherein the compositions comprise a cold solution comprising liquid water and / or ice particles, and optionally one or more additives and / or pharmacologic agents. The treatment of suprapubic fat includes cryolipolysis of the fat cells.
Owner:MIRAKI INNOVATION THINK TANK LLC

AI-assisted Raman spectroscopy system for biomarker analysis of aqueous humor

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.
Owner:REYNARD MICHAEL

Nerve stimulation for treatment of diseases and disorders

ActiveUS12491367B2ElectrotherapyArtificial respirationDiseaseEndogenous mediator
Methods are presented for treating a subject having a disease or disorder comprising stimulating a vagus nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific vagus neurogram in an amount and manner effective to treat the disease or disorder in a subject.
Owner:THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

Pupillometer with indexed light reflext output immune to medication-induced pupillary condition

A pupillometer comprising a camera, a light source, a display, and a microprocessor configured with an algorithm to generate an indexed output representing pupillary light reflex reactivity. The indexed output is substantially invariant to changes in baseline pupil size caused by pharmacologic agents such as opioids or by ambient lighting variations, thereby providing a robust and reliable measure of neurologic function across a wide range of clinical conditions.
Owner:NEUROPTICS INC